https://scholars.lib.ntu.edu.tw/handle/123456789/512639
Title: | Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations | Authors: | Chiu C.-H. Yang C.-T. JIN-YUAN SHIH Huang M.-S. Su W.-C. Lai R.-S. Wang C.-C. Hsiao S.-H. Lin Y.-C. Ho C.-L. Hsia T.-C. Wu M.-F. Lai C.-L. Lee K.-Y. Lin C.-B. Yu-Wung Yeh D. Chuang C.-Y. Chang F.-K. Tsai C.-M. Perng R.-P. Chih-Hsin CHIH-HSIN YANG |
Issue Date: | 2015 | Publisher: | Lippincott Williams and Wilkins | Journal Volume: | 10 | Journal Issue: | 5 | Start page/Pages: | 793-799 | Source: | Journal of Thoracic Oncology | Abstract: | Background: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the standard therapy for advanced lung adenocarcinomas with common EGFR mutations. Preclinical studies have suggested that uncommon G719X, L861Q, and S768I mutations are also sensitive to EGFR-TKIs. However, the efficacy of EGFR-TKIs in patients with these uncommon mutations remains unclear. Methods: A nationwide survey was performed to collect data from gefitinib and erlotinib treatment outcomes of patients with stage IIIB/IV lung adenocarcinoma bearing EGFR G719X/L861Q/S768I mutations. The results were compared with those regarding patients with exon 19 deletions or L858R mutations. Results: One hundred and sixty-one patients with uncommon EGFR mutations were enrolled from 18 institutes throughout Taiwan. Mutations of G719X, L861Q, S768I, G719X + L861Q, and G719X + S768I were observed in 78, 57, 7, 9, and 10 patients, respectively. After receiving EGFR-TKI treatment, patients with uncommon mutations exhibited a significantly inferior tumor response rate (41.6% vs. 66.5%; p < 0.001) and progression-free survival (median, 7.7 vs. 11.4 months; p < 0.001) than patients with common mutations. Among the patients who used EGFR-TKIs as first-line treatment, there was a significant difference in overall survival between these two groups of patients (median, 24.0 vs. 29.7 months; p = 0.005). Conclusion: Gefitinib and erlotinib are active in patients with G719X/L861Q/S768I mutations; however, less effective than in those with common mutations. ? 2015 by the International Association for the Study of Lung Cancer. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938278221&doi=10.1097%2fJTO.0000000000000504&partnerID=40&md5=3bb2bc32dd8b62bfab3ba40a9a189a93 https://scholars.lib.ntu.edu.tw/handle/123456789/512639 |
ISSN: | 1556-0864 | DOI: | 10.1097/JTO.0000000000000504 | SDG/Keyword: | cisplatin derivative; erlotinib; gefitinib; epidermal growth factor receptor; erlotinib; gefitinib; protein kinase inhibitor; quinazoline derivative; adult; advanced cancer; aged; cancer chemotherapy; cancer patient; cancer prognosis; cancer resistance; cancer staging; cancer survival; Conference Paper; controlled study; drug efficacy; epidermal growth factor receptor kinase gene; exon; female; gene deletion; genetic association; human; lung adenocarcinoma; major clinical study; male; mutator gene; overall survival; priority journal; progression free survival; retrospective study; Taiwan; treatment outcome; treatment response; adenocarcinoma; antagonists and inhibitors; disease free survival; genetics; Lung Neoplasms; middle aged; mutation; survival rate; very elderly; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Epidermal Growth Factor; Survival Rate; Treatment Outcome |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.